US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

3.21

+0.500018.45%

Post-market: 3.08-0.1300-4.05%19:59 EDT

Volume:1.07M

Turnover:3.28M

Market Cap:106.56M

PE:-1.04

High:3.27

Open:2.69

Low:2.62

Close:2.71

Loading ...

Overview Company News Filings

Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners

Lexeo Therapeutics price target raised to $25 from $23 at Chardan

Lexeo Therapeutics price target lowered to $19 from $20 at Leerink

BUZZ-Lexeo rises on alignment with FDA on development plan for gene therapy

Lexeo Therapeutics reaches FDA alignment on development plan for LX2006

Lexeo Therapeutics Inc: Believes Cash and Cash Equivalents as of Sept 30 Will Be Sufficient to Fund Operations Into 2027

THOMSON REUTERS

Press Release: Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Adage Capital Management, L.p. Reports 7.86% Passive Stake in Lexeo Therapeutics as of Sept 30 - SEC Filing

THOMSON REUTERS

Lexeo Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease

MT Newswires Live

Cautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment Potential

Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment

BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference

Lexeo Therapeutics Announces Positive Interim Data for Lx1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of Apoe4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS

Lexeo Therapeutics - Sees Further Lx1001 Development Plans in 2025

THOMSON REUTERS

Lexeo Therapeutics Inc - Lx1001 Well Tolerated With No Reports of Aria

THOMSON REUTERS

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy Rating

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LXEO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":3.21,"timestamp":1745265600000,"preClose":2.71,"halted":0,"volume":1065637,"hourTrading":{"tag":"盘后","latestPrice":3.08,"preClose":3.21,"latestTime":"19:59 EDT","volume":3248,"amount":10312.5378,"timestamp":1745279941402},"delay":0,"floatShares":21795584,"shares":33196997,"eps":-3.093449,"marketStatus":"Not Yet Opened","change":0.5,"latestTime":"04-21 16:00:00 EDT","open":2.69,"high":3.265,"low":2.6209,"amount":3284213.7374798,"amplitude":0.237675,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.093449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":0,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":2.71,"preHourTrading":{"tag":"盘前","latestPrice":2.71,"preClose":2.71,"latestTime":"09:25 EDT","volume":1528,"amount":4039.847112,"timestamp":1745241900039},"postHourTrading":{"tag":"盘后","latestPrice":3.08,"preClose":3.21,"latestTime":"19:59 EDT","volume":3248,"amount":10312.5378,"timestamp":1745279941402},"volumeRatio":1.54922,"impliedVol":1.2555,"impliedVolPercentile":0.427},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":21795584,"roa":"-46.11%","roe":"-85.37%","lyrEps":-3.093449,"volumeRatio":1.54922,"shares":33196997,"dividePrice":0,"high":3.265,"amplitude":0.237675,"preClose":2.71,"low":2.6209,"week52Low":1.45,"pbRate":"0.91","week52High":19.5,"institutionHeld":0,"latestPrice":3.21,"eps":-3.093449,"divideRate":0,"volume":1065637,"delay":0,"ttmEps":-3.093449,"open":2.69,"prevYearClose":6.58,"prevWeekClose":2.71,"prevMonthClose":3.47,"prevQuarterClose":3.47,"fiveDayClose":1.98,"twentyDayClose":2.71,"sixtyDayClose":5.61},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2483858809","title":"Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483858809?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:10","pubTimestamp":1731521400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 13:10 ET (18:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2483858469","title":"Lexeo Therapeutics price target raised to $25 from $23 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483858469?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:05","pubTimestamp":1731521158,"startTime":"0","endTime":"0","summary":"Chardan analyst Geulah Livshits raised the firm’s price target on Lexeo Therapeutics (LXEO) to $25 from $23 and keeps a Buy rating on the shares. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-25-from-23-at-chardan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-25-from-23-at-chardan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2483833141","title":"Lexeo Therapeutics price target lowered to $19 from $20 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833141?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:55","pubTimestamp":1731513317,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $19 from $20 and keeps an Outperform rating on the shares. The firm notes L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-19-from-20-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-19-from-20-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2483588999","title":"BUZZ-Lexeo rises on alignment with FDA on development plan for gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2483588999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483588999?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:28","pubTimestamp":1731508104,"startTime":"0","endTime":"0","summary":"** Shares of gene therapy developer Lexeo Therapeutics  rise 13.62% to $8.74 premarket   ** Co says reached alignment with FDA on registrational development plan for LX2006 to support an accelerated approval pathway   ** LX2006 is being developed as a gene therapy that is delivered intravenously for the treatment of Friedreich's ataxia cardiomyopathy   ** Friedreich's ataxia is a genetic multi-system disorder and 80% of patients are estimated to develop cardiomyopathy, a type of heart disease   ** LX2006 was granted regenerative medicine advanced therapy  designation to accelerate development - LXEO   ** Brokerage Stifel says alignment is a big win   ** Up to last close, stock down ~42% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2483974002","title":"Lexeo Therapeutics reaches FDA alignment on development plan for LX2006","url":"https://stock-news.laohu8.com/highlight/detail?id=2483974002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483974002?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:56","pubTimestamp":1731502576,"startTime":"0","endTime":"0","summary":"LX2006 for the Treatment of FA Cardiomyopathy: Regulatory Update: Alignment on key elements of accelerated development pathway following a Type C m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-reaches-fda-alignment-on-development-plan-for-lx2006?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-reaches-fda-alignment-on-development-plan-for-lx2006?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FA","BK4139","BK4130","BK4535","BK4539","LXEO"],"gpt_icon":0},{"id":"2483001507","title":"Lexeo Therapeutics Inc: Believes Cash and Cash Equivalents as of Sept 30 Will Be Sufficient to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483001507?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:30","pubTimestamp":1731501001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1XDQTC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2483013670","title":"Press Release: Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483013670?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:30","pubTimestamp":1731501000,"startTime":"0","endTime":"0","summary":"Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index  and frataxin protein expression as co-primary registrational endpoints. Received RMAT designation for LX2006 for the treatment of Friedreich ataxia  cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA. Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials. Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4535","FA","LXEO","BK4162","IHC","BK4130","ARIA"],"gpt_icon":0},{"id":"2482818250","title":"Adage Capital Management, L.p. Reports 7.86% Passive Stake in Lexeo Therapeutics as of Sept 30 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482818250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482818250?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:10","pubTimestamp":1731424236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2479877088","title":"Lexeo Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479877088","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479877088?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:52","pubTimestamp":1730375520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 07:52 ET (11:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2479733963","title":"Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2479733963","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479733963?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:04","pubTimestamp":1730300655,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  said Wednesday it has seen \"positive\" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.Treatment with the gene therapy candidate resulted in \"dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes,\" the company said.The candidate drug also showed a \"favorable safety profile,\" the company said.Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.The company's shares fell nearly 10% in recent trading.Price: 8.98, Change: -0.99, Percent Change: -9.93","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2479781470","title":"Cautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2479781470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479781470?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:15","pubTimestamp":1730297711,"startTime":"0","endTime":"0","summary":"Analyst Geulah Livshits of Chardan Capital reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), retaining the price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-optimism-for-lexeo-therapeutics-lx1001-encouraging-interim-results-and-investment-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-optimism-for-lexeo-therapeutics-lx1001-encouraging-interim-results-and-investment-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479031692","title":"Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2479031692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479031692?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:26","pubTimestamp":1730287560,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.\"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said.The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.\"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.The data were presented at th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479727672","title":"BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479727672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479727672?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:53","pubTimestamp":1730285595,"startTime":"0","endTime":"0","summary":"Oct 30  - Lexeo Therapeutics Inc   :   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE  CONFERENCE   * LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA   * LEXEO THERAPEUTICS  - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4121","GENE","LXEO"],"gpt_icon":0},{"id":"2479760452","title":"Lexeo Therapeutics Announces Positive Interim Data for Lx1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of Apoe4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479760452?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479536279","title":"Lexeo Therapeutics  - Sees Further Lx1001 Development Plans in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2479536279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479536279?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479279819","title":"Lexeo Therapeutics Inc - Lx1001 Well Tolerated With No Reports of Aria","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479279819?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479271966","title":"Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479271966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479271966?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":"Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of particip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2971504/0/en/Lexeo-Therapeutics-Announces-Positive-Interim-Data-for-LX1001-First-Ever-Gene-Therapy-to-Impact-the-Underlying-Genetic-Cause-of-APOE4-Associated-Alzheimer-s-Disease-at-the-Clinical.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","ARIA","BK4121","CSF","BK4139","LXEO","GENE"],"gpt_icon":0},{"id":"2478578965","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2478578965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478578965?lang=en_us&edition=fundamental","pubTime":"2024-10-26 03:34","pubTimestamp":1729884840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 15:34 ET (19:34 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2478373644","title":"Lexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2478373644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478373644?lang=en_us&edition=fundamental","pubTime":"2024-10-25 10:56","pubTimestamp":1729824975,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-alzheimers-treatment-advances-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-alzheimers-treatment-advances-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2477524380","title":"Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2477524380","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477524380?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:30","pubTimestamp":1729596600,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation to highlight safety and efficacy of LX1001 across four dose cohorts. NEW YORK, Oct. 22, 2024  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that interim data from the ongoing Phase 1/2 trial  of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer’s Disease  conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into thecentral nervous systemsof APOE4 homozygotes with Alzheimer’s disease.“APOE4-associated Alzheimer’s disease is a devastating, genetically distinct condition and despite recent therapeutic advances, patients with this genetic profile hav","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C6MfrF5RapjZGL3SUI9rGA--~B/aD0xNDgxO3c9Mzg0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1fb96273e5cd7873db2f9f2c6eaa0b39","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C6MfrF5RapjZGL3SUI9rGA--~B/aD0xNDgxO3c9Mzg0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1fb96273e5cd7873db2f9f2c6eaa0b39"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexeo-therapeutics-present-interim-data-113000808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXEO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1718424000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2025-04-17","current":-0.769723,"percent":0.985423,"low":-8.903248,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"high":-0.6043,"avg":-4.462675,"sd":2.064581,"marketCap":75689153},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153}],"updateTime":1745280887944}}}